Logo image
Moderate dietary supplementation with omega-3 fatty acids does not impact plasma von Willebrand Factor profile in mildly hypertensive subjects
Journal article   Open access   Peer reviewed

Moderate dietary supplementation with omega-3 fatty acids does not impact plasma von Willebrand Factor profile in mildly hypertensive subjects

Corinna S Burgin-Maunder, Peter R Brooks, Deborah Hitchen-Holmes and Fraser D Russell
BioMed Research International, 394871
2015
pdf
PDF - Published Version (Open Access)1.46 MBDownloadView
Published VersionPDF - Published Version (Open Access)CC BY V4.0 Open Access
url
https://doi.org/10.1155/2015/394871View
Published Version

Abstract

hyptensive dietary supplementation omega-3 fatty acids
Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) have blood pressure lowering and antithrombotic effects, which may benefit hypertensive patients. Increased plasma concentration of von Willebrand factor (vWF), a procoagulant glycoprotein, has been identified in patients with severe hypertension, with some, but not all studies showing an increase with mild hypertension. In this study, we determined the plasma concentration, multimer distribution, and collagen binding activity of vWF in subjects with mild hypertension and determined whether these parameters might improve after dietary supplementation with moderate amounts of LC n-3 PUFAs. Hypertensive and normotensive subjects were randomized to 12-week treatment with LC n-3 PUFAs (2.52 g/day) or placebo (canola oil). Home blood pressure measurements were recorded daily, and blood samples were collected every 3 weeks. LC n-3 PUFAs increased the n-3 index to cardioprotective levels (>8%). Plasma concentration, multimer distribution, and collagen binding activity of vWF were not reduced by LC n-3 PUFA treatment. We conclude that, at the concentration and duration used in this study, benefits of LC n-3 PUFAs in subjects with mild hypertension are not associated with a direct effect on vWF concentration or function. This trial is registered with the Australian New Zealand Clinical Trials Registry ACTRN12610000713099.

Details

Metrics

73 File views/ downloads
1074 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Web Of Science research areas
Biotechnology & Applied Microbiology
Medicine, Research & Experimental

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image